Author : P vinod kumar
Keyword : Ulcerative colitis and crohn’s disease
Subject : Gastroenterology
Article Type : Others
DOI : 10.31531/2231-5896.1000112
Article QR Code
Article File : Full Text PDF
Abstract : Vedolizumab is a fully humanized monoclonal IgG-1 antibody that selectively inhibits the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1)resulting in a reduction in local inflammation. It prevents lymphocyte translocation from the blood into the inflamed gut tissue. The outcome measures for Phase 3 and randomized clinical trials in ulcerative colitis and Crohn’s disease, was as per GEMINI 1, 2, and 3 for its efficacy. Among the vedolizumab-associated reports with serious outcomes, the drug was used for CD in 52.5% and UC in 27.4% compared with 86.1% and 13.9% for the anti-TNFs-associated reports. Although safety data from both these studies suggest VDZ is safe, larger studies with longer follow-up will be necessary. The benefit and risk profile of combining Vedolizumab with anti-TNF-α agents in the treatment of IBD will need to be examined. Vedolizumab provides an alternate class to biologic therapy with an encouraging response and safety profile.
Article by : P VINOD KUMAR
Article add date : 2021-12-16
How to cite : P vinod kumar. (2021-December-16). Vedolizumab in ulcerative colitis and crohn’s disease-a systematic review. retrieved from https://www.openacessjournal.com/abstract/928